life

Review
Up-Date on Diabetic Nephropathy
Maria Chiara Pelle 1, *,† , Michele Provenzano 2,† , Marco Busutti 2 , Clara Valentina Porcu 2 , Isabella Zaffina 1 ,
Lucia Stanga 3 and Franco Arturi 1,4

1 Department of Medical and Surgical Sciences, University “Magna Graecia” of Catanzaro,

88100 Catanzaro, Italy
2 Nephrology, Dialysis and Renal Transplant Unit, IRCCS—Azienda Ospedaliero-Universitaria di Bologna,
Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy
3 Oncology Unit, IRCCS—Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of
Bologna, 40126 Bologna, Italy
4 Research Centre for the Prevention and Treatment of Metabolic Diseases (CR METDIS),
University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
* Correspondence: [email protected]
† These authors equally contributed to this work.

Abstract: Diabetes is one of the leading causes of kidney disease. Diabetic kidney disease (DKD)
is a major cause of end-stage kidney disease (ESKD) worldwide, and it is linked to an increase in
cardiovascular (CV) risk. Diabetic nephropathy (DN) increases morbidity and mortality among
people living with diabetes. Risk factors for DN are chronic hyperglycemia and high blood pressure;
the renin-angiotensin-aldosterone system blockade improves glomerular function and CV risk in these
patients. Recently, new antidiabetic drugs, including sodium–glucose transport protein 2 inhibitors
and glucagon-like peptide-1 agonists, have demonstrated additional contribution in delaying the
progression of kidney disease and enhancing CV outcomes. The therapeutic goal is regression of
albuminuria, but an atypical form of non-proteinuric diabetic nephropathy (NP-DN) is also described.
In this review, we provide a state-of-the-art evaluation of current treatment strategies and promising
emerging treatments.
Citation: Pelle, M.C.; Provenzano, M.;
Busutti, M.; Porcu, C.V.; Zaffina, I.; Keywords: diabetic nephropathy; hyperglycemia; type 2 diabetes; pathophysiology; albuminuria;
Stanga, L.; Arturi, F. Up-Date on therapeutics
Diabetic Nephropathy. Life 2022, 12,
1202. https://doi.org/10.3390/
life12081202

Academic Editor: Juei-tang Cheng 1. Introduction

Received: 28 June 2022

Diabetes Mellitus (DM) is defined by the presence of hyperglycemia due to a deficit
Accepted: 2 August 2022
of insulin production and/or resistance. Globally, 537 million adults between the ages
Published: 8 August 2022
of 20–79 years are diabetic, and the International Diabetes Federation (IDF) predicts a
progressive increase in the number of diabetic patients up to 643 million by 2030 and to
Publisher’s Note: MDPI stays neutral
784 million by 2045 [1]. DM is characterized by micro- and macrovascular complication;
with regard to jurisdictional claims in
among the former, it is known that it causes up to 25–40% of chronic kidney disease (CKD),
published maps and institutional affil-
also called diabetic kidney disease (DKD), becoming the principal cause of kidney failure
iations.
worldwide [2]. About one-third of patients with type 1 diabetes and about 50% of patients
living with type 2 diabetes will develop CKD. According to Kidney Disease Improving
Global Outcomes Work Group (KDIGO) guidelines, CKD is defined as a reduction of
Copyright: © 2022 by the authors.
estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 and/or presence of
Licensee MDPI, Basel, Switzerland. albuminuria. This classification includes patients who have increased albuminuria but
This article is an open access article normal eGFR (stage I and II) and those who have low eGFR with or without albuminuria
distributed under the terms and (stage III, IV, and V). In fact, in large epidemiologic studies, many diabetic patients have
conditions of the Creative Commons an atypical form of non-proteinuric diabetic nephropathy (NP-DN) [3]. Risk factors for
Attribution (CC BY) license (https:// DKD are classified in two main groups: modifiable and non-modifiable ones. The for-
creativecommons.org/licenses/by/ mer, susceptible to intervention, includes hypertension, hyperglycaemia, dyslipidaemia,
4.0/). and smoking. The second group comprises age, male sex, ethnicity, genetic factors (ACE,

Life 2022, 12, 1202. https://doi.org/10.3390/life12081202 https://www.mdpi.com/journal/life

Life 2022, 12, 1202 2 of 17

APOC1, APOE, HSPG2, eNOS, VEGF, TGFβ1, PPARγ, among others) [4]. Etiology of
DKD includes multiple mechanisms such as glomerular hemodynamics (i.e., glomerular
hyperfiltration), hyperinflammation, oxidative stress, and fibrosis. A large meta-analysis
that includes about 1 million patients compared subjects with and without diabetes and
demonstrated that patients with diabetes had a risk for all-cause and cardiovascular (CV)
mortality up to two-fold more than those without. Owing to this evidence, several clinical
trials have been conducted with the purpose of slowing the progression to ESKD and reduc-
ing kidney death and CV risk. In addition, these trials evaluated the nephroprotective role
of drugs compared to the standard-of-care, often considered the renin-angiotensin-system
inhibitors (RAASi). The SONAR, the FIDELIO-DKD, and CREDENCE trials demonstrated
that endothelin-1 receptor antagonists (ERA), the novel non-steroidal mineralocorticoid re-
ceptor antagonist (MRA), and sodium-glucose co-transporter inhibitors (SGLT2is) improve
renal outcomes in DKD patients already treated with RAASi. A personalized medicine is
the best strategy to improve prognosis in DKD patients. In this review, we aim to conduct
a state-of-the-art evaluation of current treatment and promising emerging treatments.

2. Diabetic Nephropathy: State of Art

“Diabetic nephropathy” (DN) refers to a well-defined kidney disease, directly associ-
ated with a long duration of diabetes and often confirmed by histological lesions [5]. DN is
a heterogeneous disease characterized by the presence of albuminuria and/or reduction of
eGFR in people with diabetes. According to the American Diabetes Association (ADA),
pathological albuminuria is defined with an albumin-to-creatinine ratio (ACR) greater than
30 mg/g [6]. In type 1 diabetes mellitus (T1DM), it is rare to find DN in the first 10 years of
disease, whereas the incidence of nephropathy increases between 10 and 20 years after the
diagnosis (up to 3% per year). Although the duration of the disease is a strong predictor for
the onset of DN, other factors are relevant for its development, including poor glycaemic
control, uncontrolled blood pressure, and genetic susceptibility [7]. In T1DM patients,
natural evolution of DN consists of glomerular hyperfiltration and evolves step-by-step
with the onset of microalbuminuria, macroalbuminuria, and with the reduction of glomeru-
lar filtration rate (GFR) at the latest stages of the disease [3]. In type 2 diabetes mellitus
(T2DM), most cases of DN do not rigidly follow the Mogensen’s phases, depicted in 1980;
in fact, there is a greater heterogeneity in clinical presentation and according to different
ethnicities. A large cohort study showed that the prevalence of albuminuria was higher
in the Asian and Hispanic group (55%) than in Caucasian group (40,6%), likely due to
polygenic component [8]. In the United Kingdom Prospective Diabetes Study (UKPDS),
a large longitudinal cohort study, about one-third of diabetic patients developed kidney
injury, detected with the presence of eGFR reduction or albuminuria. At time of diagnosis
of T2DM, up to 3% of patients have already developed albuminuria, because frequently
initial stages move on undiagnosed or as prediabetes [9]. In a third of cases, retinopathy is
not present, unlike T1DM [10]. Albuminuria and co-existing retinopathy in T2DM are reli-
able markers of microvascular damage and thus highly suggestive of DN [11]. Presence of
albuminuria often lead to the eGFR reduction and, in a portion of cases, to end-stage kidney
disease (ESKD) [12]. However, in T2DM patients, DN can occur also without retinopathy
or albuminuria in a non-trivial number of cases, and this can make it difficult to establish
the correct timing to initiate the appropriate therapeutic intervention, mainly represented
by RAASi, SGLT2 inhibitors, and other effective nephroprotective treatments [13].
The pathogenesis of DN is complex and involves a number of mechanisms (Figure 1).
Hyperglycemia is central in the pathogenesis of DN via different pathways. Hyperglycemia
promotes the shunt of glucose metabolism toward non-glycolytic mechanisms such as
the polyol pathway, which leads to the increased production of reactive oxygen species
(ROS) [14]. The related oxidative stress increases local and systemic inflammation [15].
Moreover, oxidative stress is responsible for both direct and indirect damage to kidney
cells (podocytes, mesangial, and endothelial cells). These cells are crucial for the mod-
ulation of glomerular and the filtration glomerular capillary structure. Hyperglycemia
Life 2022, 12, 1202 3 of 17

is associated with hypertrophy and mesangial cell proliferation, matrix production, and
basement membrane thickening. Detrimental effects in the kidney cells determine pro-
teinuria and tubule-interstitial damage and fibrosis [16]. Hyperglycemia is known to be
responsible for generation of advanced glycation end-products (AGEs), which can alter the
function and structure of the kidneys and initiate morphological changes typical of DN,
leading to damage of the matrix, glomerular basement membrane, and other components
in the glomerulus. Hyperglycemia also activates protein kinase C (PKC) pathway with
production of endothelin-1 and vascular endothelial growth factor, determining glomeru-
lar damage and the direct oxidization of pivotal structures such as DNA, carbohydrates,
lipids, and proteins. ROS can induce increased PKC activation, transforming growth
factor -β (TGF-β) expression and angiotensin–II (Ang-II) levels [17], promoting fibrotic
processes in the tubule-interstitium and remodeling of the extracellular matrix in the
mesangium [14]. Moreover, Ang-II determines several effects on the kidneys, mediated by
local and systemic activation of the RAAS [18]. Hyperactivation of Ang-II causes protein-
uria, increases glomerular capillary pressure and permeability, and promotes inflammation
and macrophage infiltration, leading to the production of inflammatory and profibrotic
cytokines and extracellular matrix (ECM) remodeling. Moreover, it stimulates renal cell
proliferation and hypertrophy [19,20]. In the progression of renal disease, RAAS plays
a pivotal role [21,22]. The RAAS can be distinguished into a systemic and intra-renal
RAAS and both of them are implicated in the pathogenesis of DN lesions. Systemic RAAS
is a cascade of molecules that starts from the synthesis and secretion of renin from the
juxtaglomerular cells in the kidney [23]. Renin cleaves angiotensinogen (AGN) producing
angiotensin I (AGTI). Angiotensin I is then converted into angiotensin II (AGTII) via the
angiotensin converting enzyme (ACE). AGTII is the main effector of the RAAS and acts
through angiotensin receptors AT1 and AT2. A paracrine role of AGTII has been postulated
and proved with the discovery of high concentration of intratubular and interstitial AGTI
and AGTII. It has recently been demonstrated that renin may act independently of the
generation of AGTII, confirming the existence of an intrarenal RAAS [24]. Several studies
have also shown a reduction in circulating AGTII levels in diabetic patients, suggesting
that the effect of AGTII on accelerating the progression of kidney disease is mediated by
paracrine mechanisms in the kidney. AT1 receptor is widely expressed across the kidney
tubules, glomerular wall, and arterial vasculature. These receptors have a well-known
vasoconstrictive effect on systemic circulation and stimulate the secretion of aldosterone.
However, additional intrarenal functions, such as arterial vasoconstriction, increase in
sodium reabsorption across the tubules and regulation of tubule-glomerular feedback have
been detected [20]. AT2 receptors are mainly expressed during embryogenesis. However,
in keeping with recent experiments, it looks like moderate expression of AT2 receptors is
maintained in the adult kidney where they counteract the actions of AT1 receptors. This is
especially done through the stimulation of bradykinin, which in turn acts as vasodilator and
natriuretic peptide. At least part of the beneficial effects of angiotensin receptor antagonists
is due to the stimulation of AT2 receptors [25]. In patients with diabetes, AGTII is recog-
nized as a main mediator of chronic injury. A crucial point of pathophysiology in patients
with diabetes is the intrarenal activation of RAAS associated with an increased sensitivity
to AGTII [26]. The RAAS inhibition proved a benefit in patients with DN, by delaying
worsening of kidney function over time. However, the regulation of RAAS is complex and
still not completely understood. The intrarenal levels of renin as well as the upregulation
of renin RNA in proximal are increased in the early phases of diabetic nephropathy [27].
Moreover, the presence of hyperglycemia stimulates AGT mRNA expression in the prox-
imal tubule of the kidney, and this increased gene expression is likely mediated by the
reactive oxygen species (ROS) [28]. Hyperglycemia increases the production of superoxide
in mitochondria, which, in combination with NO, generates peroxynitrite, a marker of
vascular complications in diabetes. These findings are accompanied by the discovery of
a downregulation of AT2 receptors in DN whose activation prevents the worsening of
kidney damage in response to RAAS blockade drugs [29]. The resulting increase in AGTII
 superoxide in mitochondria, which, in combination with NO, generates peroxynitrite, a
marker of vascular complications in diabetes. These findings are accompanied by the
discovery of a downregulation of AT2 receptors in DN whose activation prevents the
Life 2022, 12, 1202 4 of 17
worsening of kidney damage in response to RAAS blockade drugs [29]. The resulting
increase in AGTII intrarenal levels are deleterious on the kidney. Both hyperglycemia
and AGTII activate the TGF-β pathway and promote extracellular matrix deposition with
intrarenal levels are deleterious on the kidney. Both hyperglycemia and AGTII activate
accumulation of collagen and fibrosis over time [30]. Interestingly, SGLT2 co-transporter
the TGF-β pathway and promote extracellular matrix deposition with accumulation of
contributes
collagen andthe
to generation
fibrosis over timeof [30].
ROS Interestingly,
[31]. SGLT2 is hyperactivated
SGLT2 in contributes
co-transporter patients withto DN,
leading to an increase
the generation of ROSin[31].
sodium
SGLT2reabsorption in theinproximal
is hyperactivated tubule.
patients with DN,This mechanism
leading to an is
associated with
increase in the reabsorption
sodium molecular dysfunction
in the proximalof other
tubule.transporters and isthe
This mechanism energy con-
associated
sumption
with the used to warrant
molecular the movement
dysfunction of sodium
of other transporters andthrough theconsumption
the energy cell membranes.
used The
to warrant
resulting the movement
increased of sodium
mitochondrial through the cell membranes.
phosphorylation The resulting
leads to a raised increased
production of ROS.
mitochondrial phosphorylation leads to a raised production of ROS.

Figure 1. Mechanisms involved in the pathogenesis of diabetic kidney disease. PKC, protein kinase
C; AGE,
Figure advanced glycated
1. Mechanisms end-product;
involved ROS, reactiveof
in the pathogenesis oxygen species;
diabetic TGF-β,
kidney transforming
disease. growthkinase
PKC, protein
factor-β; Ang, angiotensin.
C; AGE, advanced glycated end-product; ROS, reactive oxygen species; TGF-β, transforming
growth factor-β; Ang, angiotensin.
SGLT2 cotransporter expression in the apical membrane of proximal tubular cells is
pivotal in the development and progression of DN. Expression is regulated by levels of
SGLT2
blood cotransporter
glucose. Hyperglycemiaexpression
leads in
to the apical membrane
an increased expressionofofproximal
SGLT2 [32].tubular
AGTII cells is
pivotal in the
intrarenal development
levels increase the and progression
expression of DN.
of SGLT2 withExpression
a mechanism is regulated
that involves by AT1
levels of
blood
receptors [33]. Other factors are involved in the regulation of SLGT2 expression including in-
glucose. Hyperglycemia leads to an increased expression of SGLT2 [32]. AGTII
trarenal levelsnuclear
hepatocyte increase the HNF-1α
factors expression and of SGLT2[34].
HNF-3β with Thea overall
mechanism that of
regulation involves
SGLT2 AT1
expression
receptors [33].should
Otherbefactors
furtherare
clarified
involvedby confirming the importance
in the regulation of SLGT2 andexpression
interconnectionincluding
between multiple pathways (e.g., AGTII, SGLT2, ROS) in the pathogenesis
hepatocyte nuclear factors HNF-1α and HNF-3β [34]. The overall regulation of SGLT2 of DN.
expressionAdditionally,
should be aldosterone is involved
further clarified in the pathogenesis
by confirming of DN. Through
the importance the acti-
and interconnection
vation of the Smad2-dependent TGFβ1 pathway, aldosterone increases production of the
between multiple pathways (e.g., AGTII, SGLT2, ROS) in the pathogenesis of DN.
extracellular matrix protein fibronectin, by glomerular mesangial cells [35]. Moreover, al-
Additionally,
dosterone increases aldosterone is involved
collagen deposition leadingin to
the pathogenesis
matrix of DN. Through
and tubulointerstitial fibrosis, the
via acti-
vation of the Smad2-dependent
ERK1/2-dependent pathways [36].TGFβ1 pathway, aldosterone
Hyperglycemia stimulates reninincreases
and Ang-IIproduction
synthesisof the
extracellular
in mesangial cells [37]. Much evidence supports the role of interleukins (such as IL- 1, Moreover,
matrix protein fibronectin, by glomerular mesangial cells [35]. IL-18,
aldosterone
and IL-6) inincreases collagen
the progression deposition
of DN leading
[38]. Plasma levelstoof matrix and tubulointerstitial
these cytokines increase with thefibro-
sis,development of nephropathy
via ERK1/2-dependent and are independently
pathways associatedstimulates
[36]. Hyperglycemia with the development
renin and of Ang-II
albuminuria [38]. In experimental DN models, inhibition of inflammation
synthesis in mesangial cells [37]. Much evidence supports the role of interleukins (such as state has been
IL-shown to have
1, IL-18, and aIL-6)
protective
in theeffect on the kidney
progression of DN[39]. Nuclear
[38]. Plasma factor-κB
levels of(NF-κB)
these is one of in-
cytokines
the key elements involved in the inflammatory process of DN, regulating cell adhesion
crease with the development of nephropathy and are independently associated with the
proteins, inflammatory cytokines, and chemokines, ultimately contributing to kidney in-
Life 2022, 12, 1202 5 of 17

jury [40]. Cytokines and hyperglycemia can activate important pathways, such as the Janus
kinase/signal transducers and activators of transcription (JAK-STAT) pathway, which is the
main mediator between paracrine stimulation and nuclear receptors. [41]. It is upregulated
in glomerular cells in early DN and promotes NF-κB. It is activated by several stimuli,
such us hyperglycemia, mechanical stress, AGE and ROS, Ang-II, inflammatory cytokines,
and leads NF-κB to stimulate the production of proinflammatory cytokines and adhesion
molecules, establishing a vicious circle [40]. Another important pathway activated in DN is
intraglomerular hypertension, induced by glomerular hyperfiltration. It is one of the first
mechanisms responsible for the onset of albuminuria and eGFR reduction and is mediated
by glucose-dependent dilation of glomerular afferent arteries, through vasoactive media-
tors such as TGF-β1, vascular endothelial growth factor (VEGF), insulin-like growth factor
1 (IGF-1), nitric oxide (NO), prostaglandins, and glucagon [42]. Kidney hypoxia is a crucial
factor that promotes progression of DN. In diabetic people, hyperglycaemia increases
energy consumption of tubular cells, due to glomerular hyperfiltration and upregulation of
sodium–glucose cotransport [43]; moreover, loss of peritubular capillaries and interstitial
fibrosis decreases oxygen delivery [44], causing a mismatch between oxygen demand and
supply. Recent studies have also demonstrated that dysregulated autophagy is important in
physiopathology of DN; the mechanism is not fully understood and seems to play a crucial
role the mammalian target of rapamycin complex 1 (mTORC1), which negatively regulates
autophagy by inhibiting the activity of Unc-51-like kinase 1 (ULK1), a kinase important
for a start of the autophagy [45]. Animal and human studies demonstrated that inhibition
of mTORC1 by rapamycin decreases the progression of DN in diabetic db/db mice [46].
Future studies should address in more detail the interconnections between the different
pathways of damage in DN and the potential molecular target for novel pharmacological
drugs, which are eagerly expected in the context of this severe disease.

3. DN and Risk for Progression to ESKD—Novel Biomarkers

Patients with DN have a high risk for progression to end-stage kidney disease (ESKD).
In addition, they have also a very poor CV prognosis. The Alberta Kidney Disease Net-
work (AKDN) cohort and National Health and Nutrition Examination Survey (NHANES)
showed that patients with DN had a 2.7 times higher risk of acute myocardial infarction [45].
This risk was higher than the one presented in patients with diabetes (2.0) or CKD (1.4)
alone. Moreover, they also reported higher risk for all-cause mortality. Blood pressure,
age, serum lipids levels, and smoking habit play an important role in CV events in DN
patients [46]. However, hyperglycemia is a modifiable risk factor such as hypertension
and other metabolic factors. Recent studies have showed that an equally remarkable role
should be given to proteinuria (or albuminuria) and eGFR reduction, non-traditional risk
factors [47]. In diabetic patients, proteinuria acts as a CV risk modulator. Data of a cohort of
CKD subjects showed that the risk for major CV events (MACE) starts for mild–moderate
24 h-proteinuria (0.150–0.500 g/24 h) in DN subjects, compared with CKD subjects without
T2DM where the risk starts from the severe proteinuria category (>0.500 g/24 h). Histori-
cally, albuminuria is also considered as a biomarker of progression of DN and a marker of
glomerular damage, although the albuminuria classification does not include all the mech-
anisms and risk factors that are present in subjects with DN. Recently, clinical research has
focused on finding novel biomarkers. Symmetric Dimethylarginine (SDMA) is a catabolic
product of arginine-methylated proteins, excreted through the kidneys. A study from Zobel
et al. showed that SDMA is increased in patients with T2DM and microalbuminuria and is
associated with impaired renal function and CV disease [47]. Looker et al. demonstrated
that SDMA is associated with proteinuria and inversely associated with GFR in subjects
with T2DM and DN, and SDMA to asymmetric dimethylarginine (ADMA) ratio predicts
renal function decline [48]. Another study showed that SDMA, in T1DM patients with
microalbuminuria and high eGFR, is lower than the group with normoalbuminuria [49],
perhaps due to hyperfiltration. Another marker of renal damage is cystatin C; it is freely
filtered by the glomerulus and inversely correlated with eGFR [50]. Interestingly, cystatin
Life 2022, 12, 1202 6 of 17

C is less influenced by muscle mass than creatinine and it has lower inter-individual vari-
ability [51]. Blood levels of cystatin C is affected by thyroid disorders or glucocorticoid
treatment [52]. In patients with T2DM, the concentration of cystatin C is independently
associated with GFR, and its increasing is observed in patients with normoalbuminuria and
decreased GFR [53]. Another tubular damage marker is retinol-binding protein-4 (RBP-4),
a carrier of retinol in plasma that is not reabsorbed by tubular when it is damaged, so
its urinary concentration can be considered a predictive marker of DN in diabetic and
macroalbuminuric patients [54,55]. Although the plasma concentration of RBP-4 is not a
better marker of serum cystatin C or creatinine [56], in humans and animal models it is a
marker of CV risk factors and insulin resistance [57–59]. In survival models, plasma levels
of tumor necrosis factor receptors (TNFR-1 and TNFR-2) are linked with an enhanced risk
of CKD progression and ESKD. Furthermore, they may help to ameliorate risk stratification
of DN subjects [60]. Interestingly, these two biomarkers predict ESKD independently with
proteinuria, so they may play a possible predictive role in the earlier stages of DN and in
non-proteinuric phenotypes of DN. It has been hypothesized that TNFR-1 and TNFR-2
have a direct toxic effect on the kidney, activating pathways of inflammation and apoptosis.
Neutrophil gelatinase-associated lipocalin (NGAL) is produced in the renal tubule due to
inflammation injury [60]; in T2DM patients it is inversely related with eGFR, but positively
related with albuminuria [61,62]. In normoalbuminuric diabetic subjects compared to
non-diabetic control subjects, NGAL is higher [63]. Furthermore, urinary NGAL levels are
higher in T2DM diabetic patients with hyperfiltration compared to T2DM with normal
eGFR [64]. It must be said that NGAL levels could be affected by urinary tract infections,
obstructive pulmonary disease, different types of neoplasms, and preeclampsia [65]. Kid-
ney Injury Molecule -1 (KIM-1) is a type 1 transmembrane glycoprotein located in the
proximal tubules, proposed as a marker of acute kidney injury; high concentration in
T2DM patients with normal to mild albuminuria have been reported [66]. Two studies
found that the use of KIM-1 associated with pro b-type natriuretic peptide (pro-BNP)
or beta 2 microglobulin, GFR, and albuminuria in T2DM seems to improve prediction
of kidney function decline [67,68]. Another study showed that KIM-1 is not associated
with albuminuria; moreover, in a study of T1DM patients, it does not seem like it is a
predictor for progression of DN [69]. it should be noted that urinary tract disease and
sepsis can enhance urinary KIM-1 [70]. The high-sensitivity cardiac troponins (hs-cTnT and
hs-cTnI) and the NT-proBNP are currently used for diagnosis of acute coronary syndrome
and heart failure, respectively. In patients with kidney disease, the dosage of troponins
improves CV risk stratification. Similarly, NT-proBNP has been shown to predict CV and
kidney outcomes in subjects with kidney disease. Transforming growth factor-b1 (TGFb1)
is a cytokine and a mediator of kidney damage, leading to mesangial matrix expansion,
interstitial fibrosis, and glomerular membrane thickening ultimately leading to a kidney
injury and reduction in GFR [71]. In animals’ models, TGFb1 participates in podocytes
injury and apoptosis, stimulating expression of VEGF, which increases collagen deposition
in basement membrane [72]. In in vitro studies, TGFβ1 seems to lead oxidative stress in
podocytes by itself, and podocyte injury leads to proteinuria [73,74]. Furthermore, in vitro
studies showed that high glucose concentration stimulates TGFβ1 secretion and activation,
so it is proposed as mediator of DN in animal models [75,76]. A systematic review, which
included a large number of T2DM patients, showed a positive correlation with high levels
of serum and urinary TGFβ1with albuminuria [77]. Treatment with angiotensin-converting
enzyme inhibitors (ACE-i) decreased levels of TGFb1, which could be a mechanism of
nephro-protection [78]. VEGF is an important angiogenic factor [79]. In the kidney, re-
duction of oxygen delivery is a stimulus of expression of VEGF [80,81]; studies in vitro
demonstrated that chronic hyperglycemia can enhance the production of the VEGF pro-
tein [82]. In diabetic humans’ biopsies, a down regulation of VEGF-A expression is found
that is correlated with loss of podocytes [83]. Moreover, in people with T1DM and T2DM
and advanced DN, higher levels of urinary VEGF have been described [80]. There is con-
tradictory evidence in interventional studies, where both inhibition and administration
Life 2022, 12, 1202 7 of 17

of VEGF improve kidney function [84]. Soluble urokinase-type plasminogen activator

receptor (suPAR) is the circulating form of membrane protein urokinase receptor (uPAR);
both regulate cell adhesion and migration [85]. Their increased level is an independent risk
factor of CV diseases and kidney disease. Some evidence indicated suPAR such as a marker
of early kidney disease. In a cohort study that included subjects with T1DM, suPAR levels
correlated with decline in eGFR and CV risk, but not with albuminuria [86]. Conversely,
other studies demonstrated a positive correlation in T1DM and T2DM patients between
levels of suPAR and albuminuria [87,88]. Growth differentiation factor-15 (GDF-15) is a
cytokine, that is a marker of inflammation and of oxidative stress [89]. In people with
diabetes, GDF-15 seems to be a marker of impaired fasting glucose, and its higher levels
are correlated with an increased risk for several adverse outcomes, such as progression
of albuminuria in T2DM patients [90], eGFR decline and CV risk in T1DM patients [91],
and early death in patients in haemodialysis [92], and it is associated with heart failure
in general population [93]. In a post hoc analysis of the CANVAS trial, authors found
that increased plasma levels of GDF-15 were associated with 20 to 30% higher risk for
CV events, 1.5 to 2.1 higher risk for the development of heart failure and up to three-fold
higher risk for kidney outcomes, respectively; results were adjusted for albuminuria, eGFR.
Administration of canagliflozin decreased the mean level of GDF-15 as compared to levels
of start-of-treatment visit; instead, the treatment effect on future outcomes did not depend
on the GDF-15. Matrix metalloproteinases–10 (MMP-10) is involved in kidney and CV
disease [94]. In fact, evidence in patients with CKD showed that elevated concentrations
of MMP-10 are independently associated with atherosclerosis and, in T1DM patients, are
associated with DN [95,96]. Conversely, it is not associated with eGFR decline [97]. MMP-
10 remodels matrix, and its degradation products promote mesangium expansion, which
leads to nephropathy, so MMP-10 has been suggested as a reliable drug target to attenuate
the progression of retinopathy and DN [98]. Risk stratification is crucial in patients with
DN since not all patients within the same stage of disease have the same prognosis. Hence,
novel biomarkers would be helpful in the future to better classify DN patients according to
their future prognosis and to guide clinicians in assessing the correct clinical management
(Table 1).

Table 1. Summary of the principal prognostic and predictive biomarkers in diabetic nephropathy.

Biomarkers Characteristics Prognostic/Predictive Values

Increased in patients with T2DM and microalbuminuria and is
It is a catabolic product of arginine associated with impaired renal function and cardiovascular
SDMA methylated proteins, excreted through disease [34]. Is associated lower eGFR in patients with T2DM and
the kidneys DN; lower values have been observed in proteinuric patients
perhaps due to hyperfiltration [35,36]
It is a low molecular weight protein
produced by all types of nucleated cells.
It acts as inhibitor of cysteine protease The concentration of cystatin C in T2DM patients is
and is freely filtered by the renal independently associated with eGFR, and its increasing is
Cystatin C
glomeruli, then 99% reabsorbed and observed in patients with normoalbuminuria and
metabolized in the renal proximal tube. It decreased GFR [40]
is not secreted. It is also a marker of
tubular damage [38]
It is a marker of tubular damage, and its urinary concentration
can be considered a predictive marker of DN in diabetic and
It is a carrier of retinol in plasma, which
macroalbuminuric patients [41,42]. Although the plasma
RBP-4 is not reabsorbed by tubuli when they
concentration of RBP-4 is not a better marker of cystitis C or
are damaged
creatinine [43], in humans and animal models it is a marker of
insulin resistance and cardiovascular risk factors [44–46]
Life 2022, 12, 1202 8 of 17

Table 1. Cont.

Biomarkers Characteristics Prognostic/Predictive Values

Plasma levels of TNFR-1 and TNFR-2 are linked with an
They are membrane receptors that bind
enhanced risk of CKD progression and ESKD. Moreover, they
TNF alpha. It has been hypothesized that
TNFR-1 and may help to ameliorate risk stratification of DKD patients [57].
they have a direct toxic effect on the
TNFR-2 They predict ESKD in absence of proteinuria, so they may play a
kidney, activating pathways of
possible predictive role in the earlier stages of DN and in
inflammation and apoptosis
non-proteinuric phenotypes of DN
In T2DM patients, plasma levels of NGAL are inversely related to
eGFR and positively related to albuminuria [48,49]. In
It is a protein produced in the renal normoalbuminuric patients with DM compared to non-diabetic
NGAL
tubule due to inflammation injury [47] control subjects, NGAL is higher [50]. Furthermore, NGAL
urinary levels are higher in T2DM diabetic patients with
hyperfiltration compared to T2DM with normal eGFR [51]
In T2DM patients with normoalbuminuria or mild albuminuria,
its plasma concentrations are high [53]. The use of KIM-1
It is a type 1 transmembrane glycoprotein
associated with pro b-type natriuretic peptide (pro-BNP) or beta 2
located in the proximal tubules, and it is
KIM-1 microglobulin, eGFR, and albuminuria in T2DM seemed to
proposed as a marker of acute
improve prediction of kidney function decline [54,55]. It is not
kidney injury
associated with albuminuria. Moreover, in T1DM patients, it does
not seem like it is a predictor for progression of DN [56]
They are enzymes present in both skeletal
Cardiac
and cardiac muscles. They regulated Raises in their values are related to acute myocardial damage. In
troponins
muscle contraction by controlling the patients with kidney disease, the dosage of both hs-cTnT and
(hs-cTnT
calcium-mediated interaction of actin hs-cTnI improves CV risk stratification
and hs-cTnI)
and myosin
Amino terminal fragment of the
natriuretic type B peptide, normally
NT-proBNP has shown to predict CV and kidney outcomes in
NT-proBNP produced in the heart and released in the
subjects with kidney disease
case of cardiac stresses consequent to
water overload conditions
TGFβ1 seems to cause oxidative stress in podocytes by itself, and
podocyte injury leads proteinuria [60,61]. Moreover, in vitro
TGF β 1 is a cytokine and a mediator of
studies showed that high glucose concentration stimulates TGFβ1
kidney damage, leading interstitial
TGF β 1 secretion and activation, so it is proposed as a mediator of DN in
fibrosis, mesangial matrix expansion, and
animal models [62,63]. A positive correlation of high levels of
glomerular membrane thickening
serum and urinary TGFβ1with albuminuria has been reported in
a large metanalysis [64]
Studies in vitro demonstrated that chronic hyperglycemia can
increase the production of the VEGF protein [69], in diabetic
humans biopsies, it is found a down regulation of VEGF-A
VEGF is an important angiogenic
expression that is correlated with loss of podocyte [70]. Moreover,
factor [66]. In kidney, reduction of
VEGF in people with T1DM and T2DM and advanced DN, higher levels
oxygen delivery is a stimulus of
of urinary VEGF have been found. Although, there is
expression of VEGF [67,68]
contradictory evidence in intervention studies; in fact, both
inhibition and administration of VEGF has been shown to
improve kidney function [71]
Its increased levels are independent risk factors of cardiovascular
diseases and kidney disease. Some evidence indicated suPAR as a
It is the circulating form of membrane marker of early kidney disease. In a cohort study that included
protein urokinase receptor (uPAR), patients with T1DM, suPAR is correlated with decline in eGFR
suPAR
regulates both cell adhesion and cardiovascular risk, but not with albuminuria [73].
and migration [72] Conversely, in another studies, it demonstrated a positive
correlation in T1DM and T2DM patients between levels of suPAR
and albuminuria [74,75]
Life 2022, 12, 1202 9 of 17

Table 1. Cont.

Biomarkers Characteristics Prognostic/Predictive Values

Higher levels are correlated with an increased risk for several
It is a member of TGF-cytokine family,
adverse outcomes, particularly to a progression of albuminuria in
released in response to cellular stress. It
T2DM patients [77], eGFR decline and cardiovascular risk in
GDF-15 seems to have a role in regulating
T1DM patients [78], early death in patients in haemodialysis [79],
inflammatory processes, apoptosis, cell
and in the general population it is associated with incident
repair, and cell growth [76]
heart failure [80]
It is a calcium-dependent endopeptidases
It is involved in kidney and cardiovascular disease [81]. In
that contains zinc, involved in the various
patients with CKD, elevated concentrations of MMP-10 are
processes of tissue development and
MMP-10 independently associated with atherosclerosis and in T1DM
cellular homeostasis. MMP-10 remodels
patients are associated with DN [82,83]. Conversely, it is not
matrix and its degradation products
associated with eGFR decline [84]
promote mesangium expansion [85]
SDMA, Symmetric Dimethylarginine (SDMA); T2DM Type 2 diabetes mellitus; eGFR, estimated glomerular
filtration rate; RBP-4 Retinol-Binding protein 4; TNFR 1 and TNFR 2, tumor necrosis factor receptors; NGAL,
Neutrophil Gelatinase-Associated Lipocalin (NGAL); KIM-1, kidney injure moelcule-1; T1DM, Type 1 diabetes
mellitus; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; TGF β 1, transforming growth factor
beta; VEGF, vascular endothelial growth factor; suPAR, soluble urokinase plasminogen activator receptor; GDF-15,
growth differentiation factor 15; MMP-10, Matrix metalloproteinases-10; CKD, chronic kidney disease.

4. Old and New Drugs Capable of Ameliorating Risk in Patients with DN

One of the first studies in subjects with T2DM and nephropathy dates back to early
2000 [98]. Three main studies, the Collaborative Study Group (CSG) Captopril trial, the
IDNT, and the RENAAL trial, have demonstrated the safety and efficacy of angiotensin-
converting-enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs) in deceler-
ating CKD progression in subjects with DN [98–100]. On average, ACEi and ARBs led to the
reduction of about 20% of the risk of ESKD in comparison with standard-of-care. According
to this important evidence, treatment with RAASi has grown rapidly, although post hoc
analyses of these trials have showed that up to 40% of subjects were not responders to
ACEi or ARBs in term of albuminuria reduction [101,102]. This variability in efficacy (called
true variability or non-random variation) is independent of daily fluctuations (random
variation) in albuminuria and is partially explainable by several factors such as albuminuria
level at the moment of start-of-treatment with RAASi and adherence to treatment [103].
Even more importantly, the variability in albuminuria response is reproducible over time,
namely when the same drug is withdrawn and then restarted, or when other treatments
belonging to the same drug class are initiated. Moreover, variability in response to treat-
ment with RAASi was also demonstrated for secondary targets of response (off-targets)
such as uric acid, hemoglobin, and serum potassium levels [104]. Regardless of the cause
of variability, the clinical implication of these findings is that there is a high residual risk
in DN patients due to the persistence of albuminuria. For this reason, several trials have
been conducted in the past two decades with the purpose of decreasing this residual car-
diorenal risk in patients with DN. In these trials, different combinations of treatments have
been evaluated, namely dual RAAS blockade (Aliskiren + ARB/ACE in the ALTITUDE
trial; ACEi + ARB in the VA-NEPHRON-D trial), antioxidants (Bardoxolone, BEACON),
endothelin receptor antagonist (avosentan in the ASCEND trial) [105–108]. Unfortunately,
most of these trials failed to show a significant effect of treatment, or even reported a raised
CV risk in the treatment arm of the study leading to an earlier interruption of the study
itself. Two phenomena could explain these findings: (1) the ‘add-on’ effect, which consists
of adding a treatment to a drug of the same class, which did not determine a significant
response; (2) the study design of clinical trials in the past. In fact, in all the mentioned
trials, patients were randomized to receive standard-of-care or the experimental (potentially
useful) treatment without considering the likely of response to treatment in the two arms.
Two large trials, carried out in DKD patients, were published in 2019 (two decades after the
previous) [109,110]. These studies have highly found that SGLT2 inhibitors and selective
Life 2022, 12, 1202 10 of 17

ERA have an important role in slowing CKD progression. SGLT2 inhibitors are antagonists
of the SGLT-2 co-transporter, present in the early proximal renal tubule, that is capable
to reabsorb about the 90% of filtered glucose. In T2DM, SGLTs are overexpressed in the
proximal tubules, due to hyperglycemia, and this determines an increase in Angiotensin
II intrarenal synthesis. The overexpression of SGLT proteins and mRNA, also showed
in tubular cells, increases glucose reabsorption, as observed in diabetic subjects. SGLT2
inhibitors increase glycosuria, and thus determine an amelioration of glycemic control.
Furthermore, they also lead to a restoration of the normal tubule–glomerular feedback
(TGF), which is linked to the long-term protection on the kidney and anti-fibrotic and
anti-inflammatory effects, determining to a reduction of ROS production, tubule-interstitial
fibrosis, and glomerulosclerosis. Recently, dapagliflozin, an SGLT2i, has been demonstrated
to reduce the renal resistive index [111,112], with a potential enhancement of endothelial
function in the kidney. The CREDENCE trial enrolled more the 4000 patients with DKD
who were randomized to standard-of-care (one ACEi or ARB) or the SGLT2i canagliflozin
(added to standard-of-care) [110]. This large trial reported that canagliflozin warrants
a 30% lower risk of renal events (ESKD, doubling of serum creatinine and death from
renal or CV causes) when added to a RAASi. Intriguingly, a significant risk reduction was
observed in this study also in respect to secondary outcomes, which included CV death,
myocardial infarction, and hospitalization for heart failure. The CV protection of SGLT2
inhibitors was confirmed in the Canagliflozin Cardiovascular Assessment Study (CANVAS)
trial [113]. Over 10,000 patients with T2DM and high CV risk, treated with canagliflozin,
presented a 15% reduction in the risk of fatal and non-fatal CV events. Another drug class
interesting for the treatment of DN is represented by the ERA. ERA are selective antagonists
of endothelin-1 receptor A, which are capable of activation that has been associated with
the development of glomerulosclerosis and albuminuria in conditions of increased produc-
tion of endothelin-1, as it presents in CKD subjects. In addition, endothelin-1 binding to
ET receptors type A (ETAr), promoting cell proliferation, oxidative stress, inflammation,
podocyte activation, vasoconstriction, and stimulation of angiotensin II, all mechanisms
that worsen the decline of renal function [114]. Although the negative results were achieved
with avosentan [108], the more selective atrasentan has shown, in the SONAR trial, to lead
a reduction the risk of renal events (i.e., ESKD or doubling of serum creatinine) by 35%, in
addition to RAASi treatment [109]. Moreover, atrasentan was associated with hypervolemia
due to fluid retention, as demonstrated by the increasing Brain-Natriuretic-Peptide (BNP)
levels compared with placebo group. In the FIDELIO-DKD trial [115], about 5700 subjects
with DN were treated with the steroidal MRA finerenone compared to standard-of-care
(RAASi). The conclusions are very interesting: finerenone group had a 20% lower risk
of developing renal events. Moreover, the non-steroidal MRA, like the steroidal MRA,
such as Spironolactone and Eplerenone, block the binding of aldosterone to its receptors,
leading to a degradation of ENaC channels and then natriuresis. This novel drug class is
advantageous thanks to its greater affinity and selectivity for the mineralocorticoid receptor
and a low risk of serious adverse events, (i.e., hyperkalemia, gynecomastia, and decline of
kidney function). None of these studies have shown that the combination of MRA, ERA,
and SGLT2 can reduce the residual risk of CKD progression or in which patients this com-
bination could induce nephroprotection. It is really interesting, however, that these drugs
decrease the excretion of urine albumin, reducing or abolishing their adverse events each
other. For example, the natriuretic effect of SLGT2is mitigates the fluid retention associated
to ERA, through the endothelin receptor B and the hyperkalemia linked to MRAs. Another
drug class that conferred a positive result in DKD patients were glucagon-like peptide-1
receptor agonists (GLP1-RA) [116]. These agents stimulate the incretin GLP1 receptors and
thus reduce glucagon release and stimulate insulin secretion from pancreatic β-cells [117].
The AWARD-7 trial [118] evaluated the safety and efficacy of the GLP1-RA dulaglutide
in subjects with DKD and demonstrated that treatment with dulaglutide, at both doses
of 0.75 mg and 1.5 mg per day, was associated with a minor eGFR decline as compared
to insulin glargine. The aim of the AMPLITUDE-O trial was to compare CV and kidney
Life 2022, 12, 1202 11 of 17

(decrease of eGFR or increase in albuminuria) outcomes in diabetic subjects, randomized to

receive efpeglenatide or placebo, with previous history of CV disease or current presence of
CKD [119]. In the efpeglenatide group, risk for the onset of both CV and kidney events was
30% lower than the control group. The above-mentioned studies reported kidney and CV
protection, above all in the patients that manifest a positive response in the first months of
treatment, regardingHbA1c, albuminuria and blood pressure reduction. Moreover, a post
hoc analysis of the RENAAL trial emphasized that, in the losartan group, the importance of
nephroprotection, in term of ESKD risk reduction, was directly proportional to the degree
of albuminuria reduction, early after treatment initiation [120]. The same findings were
found in the ALTITUDE trial, although it was a ‘negative’ study. In fact, in this study,
subjects randomized to receive aliskiren + ACE/ARB had less than half the risk of CKD
progression as compared with those that received ACE/ARB alone [121]. A significant
learning from these relevant studies is that within each treatment group there was a con-
sistent variability in progression. The aim for next studies is to decrease variability in
response to the well-known biomarkers. Interestingly, it has been well-highlighted that a
non-negligible proportion of DN patients progress to the more advanced stages of CKD
(3 to 5) although the ACE/ARB-induced albuminuria reduction [122,123]. This controver-
sial context reveals that DN is a multifactorial and multi-marker-based disease, and that
finding novel predictive and prognostic biomarkers is crucial. The principal findings of this
study are summarized in Table 2. Despite the positive results of the more recent clinical
trials regarding the treatment of DN, many patients remain at increased cardiovascular and
kidney risk. The pharmacologic research should provide evidence on the efficacy of novel
treatments that can reduce and minimize such large residual risk.

Table 2. Key messages provided by the present study.

Key Points
• Diabetes is one of the most important causes of CKD. Diabetic kidney disease (DKD) is a major
cause of ESKD worldwide, being associated with and increased CV and all-cause mortality risk.
• Risk factors for DKD are: chronic hyperglycemia, hypertension, proteinuria (or albuminuria),
and eGFR.
• In diabetic patients, proteinuria acts like a CV risk modulator and is considered as biomarker of
progression of DN and a marker of glomerular damage. Recently, clinical research has focused
DiabeticNephropaty on finding new biomarkers.
• ACEi and ARB slow the CKD progression, but up to 40% of patients do not respond in term of
albuminuria reduction.
• Sodium-glucose transport protein 2 inhibitors (SGLT2) and glucagon-like peptide-1 agonist
have demonstrated additional contribution in slowing progression of kidney disease.
• Selective ERA confer a further 35% risk reduction of renal events added to RAASi but was also
associated with increase of fluid retention and hypervolemia.

5. Conclusions
DN is a heterogeneous disease associated with an extremely high risk of CV events,
CKD progression, disability, and all-cause mortality. The global burden is becoming
more severe, as testified by the increasing of prevalence of diabetes worldwide. For this
reason, there is a great interest in searching for prognostic biomarkers that are able to
improve risk stratification of DN patients. In this context, predictive biomarkers are also
expected in the perspective of precision medicine, being crucial to tailor pharmacological
treatment to the individual risk profile. Recent studies have clarified some concepts
regarding the comprehension of the mechanisms that influence the individual response to
cardioprotective and nephroprotective treatments. In conclusion, it is desirable that positive
evidence from clinical trials could be quickly transferred to clinical practice. Further studies
about this interesting and important topic are more than expected in the near future.
Life 2022, 12, 1202 12 of 17

Author Contributions: Conceptualization, M.C.P. and M.P.; methodology, M.C.P., M.P. and F.A.;
writing—original draft preparation M.C.P., M.P., M.B., C.V.P., I.Z. and L.S.; writing—review and
editing M.C.P., M.P., M.B., C.V.P., I.Z. and L.S.; visualization, M.C.P., M.P., M.B., C.V.P., I.Z. and L.S.;
supervision, F.A. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

AGEs Advanced glycation end-products

ADA American Diabetes Association
Ang-II Angiotensin –II
ACE-i Angiotensin-converting enzyme inhibitors
ARBs Angiotensin Receptor Blockers
ADMA Asymmetric dimethylarginine
BNP Brain-Natriuretic-Peptide
CV Cardiovascular
CKD Chronic Kidney Disease
DM Diabetes Mellitus
DN Diabetic nephropathy
DKD Diabetic kidney disease
ESKD End-stage-kidney-disease
ERA Endothelin-1 receptor antagonists
ETAr Endothelin-1 binding to ET receptors type A
eGFR Estimated glomerular filtration rate
ECM Extracellular matrix
KDIGO Global Outcomes Work Group
GLP1-RA Glucagon-like peptide-1 receptor agonists
GDF-15 Growth differentiation factor-15
hs-cTnT and hs-cTnI High-sensitivity cardiac troponins
IGF-1 Insulin-like growth factor 1
JAK-STAT Janus kinase/signal transducers and activators of transcription
KIM-1 Kidney Injury Molecule -1
mTORC1 Mammalian target of rapamycin complex 1
MACE Major cardiovascular events
MMP-10 Matrix metalloproteinases—10
MRA Mineralocorticoid receptor antagonist
NGAL Neutrophil Gelatinase-Associated Lipocalin
NO Nitric oxide
NP-DN Non-proteinuric diabetic nephropathy
NF-κB Nuclear factor-κB
PKC Protein kinase C
uPAR Protein urokinase receptor
ROS Reactive oxygen species
RAASi Renin-angiotensin-system inhibitors
RBP-4 Retinol-binding protein-4
SGLT2is Sodium-glucose co-transporter inhibitors
suPAR Soluble urokinase-type plasminogen activator receptor
SDMA Symmetric Dimethylarginine
T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
Life 2022, 12, 1202 13 of 17

TGF-β1 Transforming growth factor—β1

TNFR-1 and TNFR-2 Tumor Necrosis Factors receptors
ULK1 Unc-51-like kinase 1
VEGF Vascular endothelial growth factor

References
1. Sun, H.; Saeedi, P.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, C.; Basit, A.; Chan, J.C.N.; Mbanya, J.C.; et al.
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes
Res. Clin. Pract. 2022, 183, 109119. [CrossRef] [PubMed]
2. Alicic, R.Z.; Rooney, M.T.; Tuttle, K.R. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin. J. Am. Soc. Nephrol.
2017, 12, 2032–2045. [CrossRef] [PubMed]
3. Mogensen, C.E. How to protect the kidney in diabetic patients: With special reference to IDDM. Diabetes 1997, 46, S104–S111.
[CrossRef]
4. Mallik, R.; Chowdhury, T.A. Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes:
Past, present and future. Ther. Adv. Endocrinol. Metab. 2022, 13, 20420188221081601. [CrossRef] [PubMed]
5. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.
Am. J. Kidney Dis. 2007, 49, S12–S154. [CrossRef]
6. American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2021.
Diabetes Care 2021, 44, S151–S167. [CrossRef]
7. Rossing, P.; Hougaard, P.; Parving, H.H. Progression of microalbuminuria in type 1 diabetes: Ten-year prospective observational
study. Kidney Int. 2005, 68, 1446–1450. [CrossRef]
8. Parving, H.H.; Lewis, J.B.; Ravid, M.; Remuzzi, G.; Hunsicker, L.G.; DEMAND Investigators. Prevalence and risk factors for
microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney Int. 2006, 69, 2057–2063. [CrossRef]
9. Ali, M.K.; Bullard, K.M.; Saydah, S.; Imperatore, G.; Gregg, E.W. Cardiovascular and renal burdens of prediabetes in the USA:
Analysis of data from serial cross-sectional surveys, 1988–2014. Lancet Diabetes Endocrinol. 2018, 6, 392–403. [CrossRef]
10. He, F.; Xia, X.; Wu, X.F.; Yu, X.Q.; Huang, F.X. Diabetic retinopathy in predicting diabetic nephropathy in patients with type
2 diabetes and renal disease: A meta-analysis. Diabetologia 2013, 56, 457–466. [CrossRef]
11. Parving, H.H.; Gall, M.A.; Skøtt, P.; Jørgensen, H.E.; Løkkegaard, H.; Jørgensen, F.; Nielsen, B.; Larsen, S. Prevalence and causes
of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 1992, 41, 758–762. [CrossRef] [PubMed]
12. De Boer, I.H.; Rue, T.C.; Cleary, P.A.; Lachin, J.M.; Molitch, M.E.; Steffes, M.W.; Sun, W.; Zinman, B.; Brunzell, J.D.; Diabetes
Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group; et al.
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: An analysis of the Diabetes Control
and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch. Intern. Med. 2011, 171, 412–420.
[CrossRef] [PubMed]
13. Susztak, K.; Böttinger, E.P. Diabetic nephropathy: A frontier for personalized medicine. J. Am. Soc. Nephrol. 2006, 17, 361–367.
[CrossRef] [PubMed]
14. Krishan, P.; Chakkarwar, V.A. Diabetic nephropathy: Aggressive involvement of oxidative stress. J. Pharm. Educ. Res. 2011, 2, 35–41.
15. Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J. Clin. Investig. 2005, 115, 1111–1119. [CrossRef]
16. Duni, A.; Liakopoulos, V.; Roumeliotis, S.; Peschos, D.; Dounousi, E. Oxidative Stress in the Pathogenesis and Evolution of
Chronic Kidney Disease: Untangling Ariadne’s Thread. Int. J. Mol. Sci. 2019, 20, 3711. [CrossRef]
17. Forbes, J.M.; Coughlan, M.T.; Cooper, M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57,
1446–1454. [CrossRef]
18. Campbell, K.; Yacoub, R. Inhibition of RAS in diabetic nephropathy. Int. J. Nephrol. Renov. Dis. 2015, 8, 29–40. [CrossRef]
19. Gilbert, R.E.; Krum, H.; Wilkinson-Berka, J.; Kelly, D.J. The renin-angiotensin system and the long-term complications of diabetes:
Pathophysiological and therapeutic considerations. Diabet. Med. 2003, 20, 607–621. [CrossRef]
20. Navar, L.G.; Inscho, E.W.; Majid, D.S.A.; Imig, J.D.; Harrison-Bernard, L.M.; Mitchell, K.D. Paracrine regulation of the renal
microcirculation. Physiol. Rev. 1996, 76, 425–536. [CrossRef]
21. Wennmann, D.O.; Hsu, H.-H.; Pavenstädt, H. The renin-angiotensin-aldosterone system in podocytes. Semin. Nephrol. 2012, 32,
377–384. [CrossRef] [PubMed]
22. Ahn, J.H.; Hong, H.C.; Cho, M.J.; Kim, Y.J.; Choi, H.Y.; Eun, C.R.; Yang, S.J.; Yoo, H.J.; Kim, H.Y.; Seo, J.A.; et al. Effect of
eplerenone, a selective aldosterone blocker, on the development of diabetic nephropathy in type 2 diabetic rats. Diabetes Metab. J.
2012, 36, 128–135. [CrossRef] [PubMed]
23. Carey, R.M.; Siragy, H.M. The intrarenal renin-angiotensin system and diabetic nephropathy. Trends Endocrinol. Metab. 2003, 14,
274–281. [CrossRef]
24. Nguyen, G.; Delarue, F.; Burcklé, C.; Bouzhir, L.; Giller, T.; Sraer, J.D. Pivotal role of the renin/prorenin receptor in angiotensin II
production and cellular responses to renin. J. Clin. Investig. 2002, 109, 1417–1427. [CrossRef]
25. Siragy, H.M.; Carey, R.M. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension 1999,
33, 1237–1242. [CrossRef]
Life 2022, 12, 1202 14 of 17

26. Price, D.A.; Porter, L.E.; Gordon, M.; Fisher, N.D.; De’Oliveira, J.M.; Laffel, L.M.; Passan, D.R.; Williams, G.H.; Hollenberg, N.K.
The paradox of the low-renin state in diabetic nephropathy. J. Am. Soc. Nephrol. 1999, 10, 2382–2391. [CrossRef]
27. Choi, K.C.; Kim, N.H.; An, M.R.; Kang, D.G.; Kim, S.W.; Lee, J. Alterations of intrarenal renin-angiotensin and nitric oxide systems
in streptozotocin-induced diabetic rats. Kidney Int. Suppl. 1997, 60, S23–S27.
28. Hsieh, T.J.; Zhang, S.L.; Filep, J.G.; Tang, S.S.; Ingelfinger, J.R.; Chan, J.S. High glucose stimulates angiotensinogen gene expression
via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology 2002, 143, 2975–2985. [CrossRef]
29. Bonnet, F.; Candido, R.; Carey, R.M.; Casley, D.; Russo, L.M.; Osicka, T.M.; Cooper, M.E.; Cao, Z. Renal expression of angiotensin
receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. J. Hyperten. 2002, 20, 1615–1624. [CrossRef]
30. Provenzano, M.; Andreucci, M.; Garofalo, C.; Faga, T.; Michael, A.; Ielapi, N.; Grande, R.; Sapienza, P.; Franciscis, S.;
Mastroroberto, P.; et al. The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular
Disease: A Light at the End of the Tunnel? Biomolecules 2020, 10, 154. [CrossRef]
31. Llorens-Cebrià, C.; Molina-Van den Bosch, M.; Vergara, A.; Jacobs-Cachá, C.; Soler, M.J. Antioxidant Roles of SGLT2 Inhibitors in
the Kidney. Biomolecules 2022, 12, 143. [CrossRef] [PubMed]
32. Vallon, V.; Komers, R. Pathophysiology of the diabetic kidney. Compr. Physiol. 2011, 1, 1175–1232. [PubMed]
33. Osorio, H.; Bautista, R.; Rios, A.; Franco, M.; Santamaría, J.; Escalante, B. Effect of treatment with losartan on salt sensitivity and
SGLT2 expression in hypertensive diabetic rats. Diabetes Res. Clin. Pract. 2009, 86, e46–e49. [CrossRef]
34. Freitas, H.S.; Schaan, B.D.; David-Silva, A.; Sabino-Silva, R.; Okamoto, M.M.; Alves-Wagner, A.B.; Mori, R.C.; Machado, U.F.
SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1alpha and HNF-3beta. Mol. Cell Endocrinol. 2009, 305,
63–70. [CrossRef] [PubMed]
35. Lai, L.; Chen, J.; Hao, C.M.; Lin, S.; Gu, Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-beta1
pathway in mesangial cells. Biochem. Res. Commun. 2006, 348, 70–75. [CrossRef] [PubMed]
36. Nagai, Y.; Miyata, K.; Sun, G.P.; Rahman, M.; Kimura, S.; Miyatake, A.; Kiyomoto, H.; Kohno, M.; Abe, Y.; Yoshizumi, M.; et al.
Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension
2005, 46, 1039–1045. [CrossRef]
37. Vidotti, D.B.; Casarini, D.E.; Cristovam, P.C.; Leite, C.A.; Schor, N.; Boim, M.A. High glucose concentration stimulates intracellular
renin activity and angiotensin II generation in rat mesangial cells. Am. J. Physiol. 2004, 286, F1039–F1045. [CrossRef]
38. Navarro, J.F.; Mora, C. Role of inflammation in diabetic complications. Nephrol. Dial. Transplant. 2005, 20, 2601–2604. [CrossRef]
39. Awad, A.S.; Kinsey, G.R.; Khutsishvili, K.; Gao, T.; Bolton, W.K.; Okusa, M.D. Monocyte/macrophage chemokine receptor CCR2
mediates diabetic renal injury. Am. J. Physiol Ren. Physiol. 2011, 301, F1358–F1366. [CrossRef]
40. Navarro-González, J.F.; Mora-Fernández, C.; Muros de Fuentes, M.; García-Pérez, J. Inflammatory molecules and pathways in the
pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 2011, 7, 327–340. [CrossRef]
41. Pérez-Morales, R.E.; del Pino, M.D.; Valdivielso, J.M.; Ortiz, A.; Mora-Fernández, C.; Navarro-González, J.F. Inflammation in
diabetic kidney disease. Nephron 2019, 143, 12–16. [CrossRef] [PubMed]
42. Rivero, A.; Mora, C.; Muros, M.; Garcia, J.; Herrera, H.; Navarro-Gonzalez, J.F. Pathogenic perspectives for the role of inflammation
in diabetic nephropathy. Clin. Sci. 2009, 116, 479–492. [CrossRef] [PubMed]
43. Hesp, A.C.; Schaub, J.A.; Prasad, P.V.; Vallon, V.; Laverman, G.D.; Bjornstad, P.; van Raalte, D.H. The role of renal hypoxia in the
pathogenesis of diabetic kidney disease: A promising target for newer renoprotective agents including SGLT2 inhibitors? Kidney
Int. 2020, 98, 579–589. [CrossRef]
44. Nangaku, M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J. Am. Soc.
Nephrol. 2006, 17, 17–25. [CrossRef]
45. Ding, Y.; Choi, M.E. Autophagy in diabetic nephropathy. J. Endocrinol. 2015, 224, R15–R30. [CrossRef]
46. Mori, H.; Inoki, K.; Masutani, K.; Wakabayashi, Y.; Komai, K.; Nakagawa, R.; Guan, K.L.; Yoshimura, A. The mTOR pathway is
highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential. Biochem. Biophys. Res. Commun. 2009,
384, 471–475. [CrossRef]
47. Zobel, E.H.; von Scholten, B.J.; Reinhard, H.; Persson, F.; Teerlink, T.; Hansen, T.W.; Parving, H.; Jacobsen, P.K.; Rossing, P.
Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in
kidney function in persons with type 2 diabetes and microalbuminuria. Cardiovasc. Diabetol. 2017, 16, 888–896. [CrossRef]
48. Looker, H.C.; Colombo, M.; Hess, S.; Brosnan, M.J.; Farran, B.; Dalton, R.N.; Wong, M.C.; Turner, C.; Palmer, C.N.;
Nogoceke, E.; et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015, 88, 888–896.
[CrossRef]
49. Marcovecchio, M.L.; Dalton, R.N.; Turner, C.; Prevost, A.T.; Widmer, B.; Amin, R.; Dunger, D.B. Symmetric dimethylarginine, an
endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes. Arch.
Dis. Child. 2010, 95, 119–124. [CrossRef]
50. El-Khoury, J.M.; Bunch, D.R.; Hu, B.; Payto, D.; Reineks, E.Z.; Wang, S. Comparison of symmetric dimethylarginine with
creatinine, cystatin C and their eGFR equations as markers of kidney function. Clin. Biochem. 2016, 49, 1140–1143. [CrossRef]
51. Stevens, L.A.; Schmid, C.H.; Greene, T.; Li, L.; Beck, G.J.; Joffe, M.M.; Froissart, M.; Kusek, J.W.; Zhang, Y.L.; Coresh, J.; et al.
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int. 2009, 75, 652–660. [CrossRef] [PubMed]
52. Fricker, M.; Wiesli, P.; Brändle, M.; Schwegler, B.; Schmid, C. Impact of thyroid dysfunction on serum cystatin C. Kidney Int. 2003,
63, 1944–1947. [CrossRef] [PubMed]
Life 2022, 12, 1202 15 of 17

53. Kim, S.S.; Song, S.H.; Kim, I.J.; Jeon, Y.K.; Kim, B.H.; Kwak, I.S.; Lee, E.K.; Kim, Y.K. Urinary cystatin C and tubular proteinuria
predict progression of diabetic nephropathy. Diabetes Care 2013, 36, 656–661. [CrossRef] [PubMed]
54. Domingos, M.A.; Moreira, S.R.; Gomez, L.; Goulart, A.; Lotufo, P.A.; Benseñor, I.; Titan, S. Urinary Retinol-Binding Protein:
Relationship to Renal Function and Cardiovascular Risk Factors in Chronic Kidney Disease. PLoS ONE 2016, 11, e0162782.
[CrossRef]
55. Zeni, L.; Norden, A.; Cancarini, G.; Unwin, R.J. A more tubulocentric view of diabetic kidney disease. J. Nephrol. 2017, 30, 701–717.
[CrossRef] [PubMed]
56. Donadio, C.; Lucchesi, A.; Ardini, M.; Giordani, R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of
glomerular filtration rate: Comparison with plasma creatinine. J. Pharm Anal. 2001, 24, 835–842. [CrossRef]
57. Park, S.E.; Lee, N.S.; Park, J.W.; Rhee, E.J.; Lee, W.Y.; Oh, K.W.; Park, S.W.; Park, C.Y.; Youn, B.S. Association of urinary RBP4 with
insulin resistance, inflammation, and microalbuminuria. Eur. J. Endocrinol. 2014, 171, 443–449. [CrossRef]
58. Cabré, A.; Lázaro, I.; Girona, J.; Manzanares, J.; Marimón, F.; Plana, N.; Heras, M.; Masana, L. Retinol-binding protein 4 as a
plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. J. Intern Med. 2007, 262, 496–503. [CrossRef]
59. Mohapatra, J.; Sharma, M.; Acharya, A.; Pandya, G.; Chatterjee, A.; Balaraman, R.; Jain, M.R. Retinol-binding protein 4: A possible
role in cardiovascular complications. Br. J. Pharmacol. 2011, 164, 1939–1948. [CrossRef]
60. Singer, E.; Markó, L.; Paragas, N.; Barasch, J.; Dragun, D.; Müller, D.N.; Budde, K.; Schmidt-Ott, K.M. Neutrophil gelatinase-
associated lipocalin: Pathophysiology and clinical applications. Acta Physiol. 2013, 207, 663–672. [CrossRef]
61. Kern, E.F.; Erhard, P.; Sun, W.; Genuth, S.; Weiss, M.F. Early urinary markers of diabetic kidney disease: A nested case-control
study from the Diabetes Control and Complications Trial (DCCT). Am. J. Kidney Dis. 2010, 55, 824–834. [CrossRef] [PubMed]
62. Fu, W.J.; Xiong, S.L.; Fang, Y.G.; Wen, S.; Chen, M.L.; Deng, R.T.; Zheng, L.; Wang, S.B.; Pen, L.F.; Wang, Q. Urinary tubular
biomarkers in short-term type 2 diabetes mellitus patients: A cross-sectional study. Endocrine 2012, 41, 82–88. [CrossRef] [PubMed]
63. Vijay, S.; Hamide, A.; Senthilkumar, G.P.; Mehalingam, V. Utility of urinary biomarkers as a diagnostic tool for early diabetic
nephropathy in patients with type 2 diabetes mellitus. Diabetes Met. Syndr. 2018, 12, 649–652. [CrossRef]
64. Fu, W.J.; Li, B.L.; Wang, S.B.; Chen, M.L.; Deng, R.T.; Ye, C.Q.; Liu, L.; Fang, A.J.; Xiong, S.L.; Wen, S.; et al. Changes of the tubular
markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res. Clin. Pract. 2012, 95, 105–109. [CrossRef]
65. Giasson, J.; Li, G.H.; Chen, Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury
(AKI) diseases. Inflamma Allergy Drug Targets 2011, 10, 272–282. [CrossRef] [PubMed]
66. De Carvalho, J.A.M.; Tatsch, E.; Hausen, B.S.; Bollick, Y.; Moretto, M.B.; Duarte, T.; Duarte, M.M.; Londero, S.W.; Premaor, M.O.;
Comin, F.V.; et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular
damage in normoalbuminuric patients with type 2 diabetes. Clin. Biochem. 2015, 49, 232–236. [CrossRef] [PubMed]
67. Kammer, M.; Heinzel, A.; Willency, J.A.; Duffin, K.L.; Mayer, G.; Simons, K.; Gerl, M.J.; Klose, C.; Heinze, G.; Reindl-
Schwaighofer, R.; et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination
of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 2019, 96, 1381–1388. [CrossRef]
68. Nauta, F.L.; Boertien, W.E.; Bakker, S.J.; van Goor, H.; van Oeveren, W.; de Jong, P.E.; Bilo, H.; Gansevoort, R.T. Glomerular and
tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011, 34, 975–981. [CrossRef]
69. Colombo, M.; Valo, E.; McGurnaghan, S.J.; Sandholm, N.; Blackbourn, L.; Dalton, R.N.; Dunger, D.; Groop, P.H.; McKeigue, P.M.;
Forsblom, C.; et al. Biomarker panels associated with progression of renal disease in type 1 diabetes. Diabetologia 2019, 62,
1616–1627. [CrossRef]
70. Moresco, R.N.; Bochi, G.V.; Stein, C.S.; De Carvalho, J.; Cembranel, B.M.; Bollick, Y.S. Urinarykidneyinjury molecule-1 in
renaldisease. Clin. Chim. Acta 2018, 487, 15–21. [CrossRef]
71. Sureshbabu, A.; Muhsin, S.A.; Choi, M.E. TGF-βsignaling in the kidney: Profibrotic and protective effects. Am. J. Physiol. Ren.
Physiol. 2015, 310, F596–F606. [CrossRef] [PubMed]
72. Chen, S.; Kasama, Y.; Lee, J.S.; Jim, B.; Marin, M.; Ziyadeh, F.N. Podocyte-derived vascular endothelial growth factor mediates
the stimulation of alpha3 (IV) collagen production by transforming growth factor-beta1 in mouse podocytes. Diabetes 2004, 53,
2939–2949. [CrossRef] [PubMed]
73. Lee, H.B.; Yu, M.R.; Yang, Y.; Jiang, Z.; Ha, H. Transforming growth factor β1-induced apoptosis inpodocytes via the extracellular
signal-regulatedkinase-mammalian target of rapamycin complex1-NADPH oxidase 4 Axis. J. Am. Soc. Nephrol. 2005, 14,
S241–S245. [CrossRef] [PubMed]
74. Nagata, M. Podocyte injury and its consequences. Kidney Int. 2016, 89, 1221–1230. [CrossRef] [PubMed]
75. Ziyadeh, F.N. Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J. Am. Soc Nephrol. 2004, 15,
S55–S57. [CrossRef]
76. Hoffman, B.B.; Sharma, K.; Zhu, Y.; Ziyadeh, F.N. Transcriptional activation of transforming growth factor-beta1 in mesangial cell
culture by high glucose concentration. Kidney Int. 1998, 54, 1107–1116. [CrossRef]
77. Qiao, Y.C.; Chen, Y.L.; Pan, Y.H.; Ling, W.; Tian, F.; Zhang, X.X.; Zhao, H.L. Changes of transforming growth factor beta 1 in
patients with type 2 diabetes and diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis. Medicine
2017, 96, e6583. [CrossRef]
78. Andrésdóttir, G.; Jensen, M.L.; Carstensen, B.; Parving, H.H.; Rossing, K.; Hansen, T.W.; Rossing, P. Improved survival and
renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care 2014, 37,
1660–1667. [CrossRef]
Life 2022, 12, 1202 16 of 17

79. Khamaisi, M.; Schrijvers, B.F.; De Vriese, A.S.; Raz, I.; Flyvbjerg, A. The emerging role of VEGF in diabetic kidney disease. Nephrol.
Dial. Transpl. 2018, 18, 1427–1430. [CrossRef]
80. Mayer, G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol. Dial. Transplant. 2011, 26,
1132–1137. [CrossRef]
81. Ramakrishnan, S.; Anand, V.; Roy, S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J. Neuroimmune
Pharmacol. 2014, 9, 142–160. [CrossRef] [PubMed]
82. Aiello, L.P.; Wong, J.S. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. Suppl. 2000, 77,
S113–S119. [CrossRef] [PubMed]
83. Baelde, H.J.; Eikmans, M.; Lappin, D.W.; Doran, P.P.; Hohenadel, D.; Brinkkoetter, P.T.; van der Woude, F.J.; Waldherr, R.;
Rabelink, T.J.; de Heer, E.; et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte
loss. Kidney Int. 2007, 71, 637–645. [CrossRef] [PubMed]
84. Schrijvers, B.F.; Flyvbjerg, A.; Tilton, R.G.; Rasch, R.; Lameire, N.H.; De Vriese, A.S. Pathophysiological role of vascular endothelial
growth factor in the remnant kidney. Nephron. Exp. Nephrol. 2005, 101, e9–e15. [CrossRef]
85. Hayek, S.S.; Quyyumi, A.A.; Reiser, J. Soluble Urokinase Receptor and Chronic Kidney Disease. N. Engl. J. Med. 2016, 374, 891.
[CrossRef]
86. RotbainCurovic, V.; Theilade, S.; Winther, S.A.; Tofte, N.; Eugen-Olsen, J.; Persson, F.; Hansen, T.W.; Jeppesen, J.; Rossing, P.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in
Patients with Type 1 Diabetes. Diabetes Care 2019, 42, 1112–1119. [CrossRef]
87. Theilade, S.; Lyngbaek, S.; Hansen, T.W.; Eugen-Olsen, J.; Fenger, M.; Rossing, P.; Jeppesen, J.L. Soluble urokinase plasminogen
activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. J. Intern. Med. 2015, 277,
362–371. [CrossRef]
88. Guthoff, M.; Wagner, R.; Randrianarisoa, E.; Hatziagelaki, E.; Peter, A.; Häring, H.U.; Fritsche, A.; Heyne, N. Soluble urokinase
receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus. Sci. Rep. 2017, 7, 40627. [CrossRef]
89. Adela, R.; Banerjee, S.K. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.
J. Diabetes Res. 2015, 2015, 490842. [CrossRef]
90. Hellemons, M.E.; Mazagova, M.; Gansevoort, R.T.; Henning, R.H.; de Zeeuw, D.; Bakker, S.J.; Lambers-Heerspink, H.J.;
Deelman, L.E. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care
2012, 35, 2340–2346. [CrossRef]
91. Lajer, M.; Jorsal, A.; Tarnow, L.; Parving, H.H.; Rossing, P. Plasma growth differentiation factor-15 independently predicts
all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy.
Diabetes Care 2010, 33, 1567–1572. [CrossRef] [PubMed]
92. Yilmaz, H.; Çelik, H.T.; Gurel, O.M.; Bilgic, M.A.; Namuslu, M.; Bozkurt, H.; Ayyildiz, A.; Inan, O.; Bavbek, N.; Akcay, A. Increased
serum levels of GDF-15 associated with mortality and subclinical atherosclerosis in patients on maintenance hemodialysis. Herz
2015, 40, 305–312. [CrossRef] [PubMed]
93. Wang, T.J.; Wollert, K.C.; Larson, M.G.; Coglianese, E.; McCabe, E.L.; Cheng, S.; Ho, J.E.; Fradley, M.G.; Ghorbani, A.;
Xanthakis, V.; et al. Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation
2012, 126, 1596–1604. [CrossRef] [PubMed]
94. Kousios, A.; Kouis, P.; Panayiotou, A.G. Matrix Metalloproteinases and Subclinical Atherosclerosis in Chronic Kidney Disease: A
Systematic Review. Int. J. Nephrol. 2016, 2016, 9498013. [CrossRef]
95. Coll, B.; Rodríguez, J.A.; Craver, L.; Orbe, J.; Martínez-Alonso, M.; Ortiz, A.; Díez, J.; Beloqui, O.; Borras, M.; Valdivielso, J.M.; et al.
Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney
disease. Kidney Int. 2010, 78, 1275–1280. [CrossRef]
96. Toni, M.; Hermida, J.; Goñi, M.J.; Fernández, P.; Parks, W.C.; Toledo, E.; Montes, R.; Díez, N. Matrix metalloproteinase-10 plays an
active role in microvascular complications in type 1 diabetic patients. Diabetologia 2013, 56, 2743–2752. [CrossRef]
97. Carlsson, A.C.; Ingelsson, E.; Sundström, J.; Carrero, J.J.; Gustafsson, S.; Feldreich, T.; Stenemo, M.; Larsson, A.; Lind, L.; Ärnlöv, J.
Use of Proteomics to Investigate Kidney Function Decline over 5 Years. Clin. J. Soc. Nephrol. 2017, 12, 1226–1235. [CrossRef]
98. De Zeeuw, D.; Heerspink, H.J.L. Time for clinical decision support systems tailoring individual patient therapy to improve renal
and cardiovascular outcomes in diabetes and nephropathy. Nephrol. Dial Transplant. 2020, 35, ii38–ii42. [CrossRef]
99. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.;
Shahinfar, S.; et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropthy.
N. Engl. J. Med. 2001, 345, 861–869. [CrossRef]
100. Lewis, E.J.; Hunsicker, L.G.; Clarke, W.R.; Berl, T.; Pohl, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R.; Raz, I.; et al.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N. Engl. J. Med. 2001, 345, 851–860. [CrossRef]
101. Petrykiv, S.I.; de Zeeuw, D.; Persson, F.; Rossing, P.; Gansevoort, R.T.; Laverman, G.D.; Heerspink, H.J.L. Variability in response to
albuminuria-lowering drugs: True or random? Br. J. Clin. Pharmacol. 2017, 83, 1197–1204. [CrossRef] [PubMed]
102. Schievink, B.; de Zeeuw, D.; Parving, H.H.; Rossing, P.; Lambers Heerspink, H.J. The renal protective effect of angiotensin receptor
blockers depends on intra-individual response variation in multiple risk markers. Br. J. Clin. Pharmacol. 2015, 80, 678–686.
[CrossRef] [PubMed]
Life 2022, 12, 1202 17 of 17

103. Provenzano, M.; Garofalo, C.; Chiodini, P.; Mancuso, C.; Barbato, E.; De Nicola, L.; Andreucci, M. Ruolo della proteinuria nella
ricerca clinica: Per ogni vecchia risposta, una nuova domanda [Role of proteinuria in clinicalresearch: For eachold-answer, a new
key-question.]. Recenti. Prog. Med. 2020, 111, 74–81. (In Italian) [CrossRef] [PubMed]
104. Laverman, G.D.; de Zeeuw, D.; Navis, G. Between-patient differences in the renal response to renin-angiotensin system interven-
tion: Clue to optimisingrenoprotective therapy? J. Renin. Angiotensin Aldosterone Syst. 2002, 3, 205–213. [CrossRef]
105. Parving, H.H.; Brenner, B.M.; McMurray, J.J.; de Zeuww, D.; Haffner, S.M.; Solomon, S.D.; Chaturvedi, N.; Persson, F.; Desai, A.S.;
Nicolaides, M.; et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 2012, 367, 2204–2213.
[CrossRef]
106. De Zeeuw, D.; Akizawa, T.; Audhya, P.; Bakris, G.; Chin, M.; Christ-Schmidt, H.; Goldsberry, A.; Houser, M.; Krauth, M.;
Heerspink, H.J.L.; et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Eng. J. Med. 2013, 369,
2492–2503. [CrossRef]
107. Fried, L.F.; Duckworth, W.; Zhang, J.H.; O’Connor, T.; Brophy, M.; Emanuele, N.; Huang, G.D.; McCullough, P.A.; Palevsky, P.M.;
Seliger, S.; et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment
of diabetic nephropathy (VA NEPHRON-D). Clin. J. Am. Soc. Nephrol. 2009, 4, 361–368. [CrossRef]
108. Mann, J.F.; Green, D.; Jamerson, K.; Ruilope, L.M.; Kuranoff, S.J.; Littke, T.; Viberti, G.; ASCEND Study Group. Avosentan for
overt diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21, 527–535. [CrossRef]
109. Heerspink, H.J.L.; Parving, H.H.; Andress, D.L.; Bakris, G.; Correa-Rotter, R.; Hou, F.-F.; Kitzman, D.W.; Kohan, D.; Makino, H.;
McMurray, J.J.V.; et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A
double-blind, randomised, placebo-controlled trial. Lancet 2019, 393, 1937–1947. [CrossRef]
110. Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.;
Bull, S.; et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 2019, 380, 2295–2306.
[CrossRef]
111. Solini, A.; Giannini, L.; Seghieri, M.; Vitolo, E.; Taddei, S.; Ghiadoni, L.; Bruno, R.M. Dapagliflozin acutely improvesendothelial
dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: Apilot study. Cardiovasc. Diabetol. 2017,
16, 138. [CrossRef] [PubMed]
112. Provenzano, M.; Rivoli, L.; Garofalo, C.; Faga, T.; Pelagi, E.; Perticone, M.; Serra, R.; Michael, A.; Comi, N.; Andreucci, M. Renal
resistive index in chronickidneydiseasepatients: Possibledeterminants and riskprofile. PLoS ONE 2020, 15, e0230020. [CrossRef]
113. Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R.; et al.
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017, 377, 644–657. [CrossRef] [PubMed]
114. Provenzano, M.; Andreucci, M.; Garofalo, C.; Minutolo, R.; Serra, R.; De Nicola, L. Selective endothelin A receptor antagonism in
patients with proteinuric chronic kidney disease. Expert Opin. Investig. Drugs 2021, 30, 253–262. [CrossRef]
115. Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; et al.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229. [CrossRef]
116. Sawaf, H.; Thomas, G.; Taliercio, J.J.; Nakhoul, G.; Vachharajani, T.J.; Mehdi, A. Therapeutic Advances in Diabetic Nephropathy.
J. Clin. Med. 2022, 11, 378. [CrossRef]
117. Tanaka, T.; Higashijima, Y.; Wada, T.; Nangaku, M. The potential for renoprotection with incretin-based drugs. Kidney Int. 2014,
86, 701–711. [CrossRef]
118. Tuttle, K.R.; Lakshmanan, M.C.; Rayner, B.; Busch, R.S.; Zimmermann, A.G.; Woodward, D.B.; Botros, F.T. Dulaglutide versus
insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicentre,
open-label, randomised trial. Lancet Diabetes Endocrinol. 2018, 6, 605–617. [CrossRef]
119. Gerstein, H.C.; Sattar, N.; Rosenstock, J.; Ramasundarahettige, C.; Pratley, R.; Lopes, R.D.; Lam, C.S.P.; Khurmi, N.S.; Heenan, L.;
Del Prato, S.; et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 896–907.
[CrossRef]
120. De Zeeuw, D.; Remuzzi, G.; Parving, H.H.; Keane, W.F.; Zhang, Z.; Shahinfar, S.; Snappin, S.; Cooper, M.E.; Mitch, W.E.;
Brenner, B.M. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL.
Kidney Int. 2004, 65, 2309–2320. [CrossRef]
121. Heerspink, H.J.; Ninomiya, T.; Persson, F.; Brenner, B.M.; Brunel, P.C.; Chaturverdi, N.; Desai, A.; Haffner, S.M.; McMurray, J.J.;
Solomon, S.; et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the
ALTITUDE trial. Diabetes Obes. Metab. 2016, 18, 169–177. [CrossRef] [PubMed]
122. MacIsaac, R.J.; Ekinci, E.I.; Jerums, G. ‘Progressive diabetic nephropathy. How useful is microalbuminuria?: Contra’. Kidney Int.
2014, 86, 50–57. [CrossRef] [PubMed]
123. Perkins, B.A.; Ficociello, L.H.; Roshan, B.; Warram, J.H.; Krolewski, A.S. In patients with type 1 diabetes and new-onset
microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int.
2010, 77, 57–64. [CrossRef]